BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026

Benzinga03-25

BiomX (AMEX:PHGE) reported quarterly losses of $(3.36) per share which missed the analyst consensus estimate of $(2.56) by 31.25 percent. This is a 34.12 percent increase over losses of $(5.10) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2522704473?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-25 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522704473","market":"us","top_or_hot":-1,"title":"BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026","media":"Benzinga","content":"<html><body><p>BiomX (AMEX:PHGE) reported quarterly losses of $(3.36) per share which missed the analyst consensus estimate of $(2.56) by 31.25 percent. This is a 34.12 percent increase over losses of $(5.10) per share from the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-03-25 18:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>BiomX (AMEX:PHGE) reported quarterly losses of $(3.36) per share which missed the analyst consensus estimate of $(2.56) by 31.25 percent. This is a 34.12 percent increase over losses of $(5.10) per share from the same period last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHGE","symbol_name":"BiomX Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/03/44470156/biomx-fy-2024-gaap-eps-3-36-misses-2-56-estimate-biomxs-cash-balance-and-restricted-cash-as-of-dece","article_id":"2522704473","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522704473","pubTimestamp":1742898789,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"BiomX (AMEX:PHGE) reported quarterly losses of $(3.36) per share which missed the analyst consensus estimate of $(2.56) by 31.25 percent. This is a 34.12 percent increase over losses of $(5.10) per share from the same","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PHGE":"BiomX Inc."},"translate_title":"BioMX 2024财年GAAP每股收益(3.36)美元低于预期(2.56)美元，截至2024年12月31日，BiomX的现金余额和限制性现金为1800万美元，不包括公司2025年2月融资轮中额外筹集的1200万美元总收益。BiomX估计其现金、现金等价物和短期存款足以为其2026年第一季度的运营提供资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHGE":0.9},"content_text":"BiomX (AMEX:PHGE) reported quarterly losses of $(3.36) per share which missed the analyst consensus estimate of $(2.56) by 31.25 percent. This is a 34.12 percent increase over losses of $(5.10) per share from the same period last year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}